Jade Biosciences grants director 34,843 stock options
Jade Biosciences director Christopher W. Cain received a grant of stock options covering 34,843 shares of common stock at an exercise price of $15.22 per share.
Rhea-AI Filing Summary
Jade Biosciences director Christopher W. Cain received a grant of stock options covering 34,843 shares of common stock at an exercise price of $15.22 per share. The option vests in full on the earlier of June 9, 2027 or the next annual stockholder meeting, subject to his continued service.
Under an arrangement with Fairmount Funds Management LLC, Cain holds this option for one or more Fairmount investment funds and must turn over any net cash or stock to Fairmount for those funds. Both Cain and Fairmount disclaim beneficial ownership of the option and underlying shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 34,843 shares
Grant/Award
1 txn
Insider
CAIN CHRISTOPHER W.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 34,843 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 34,843 contracts (Direct)
Footnotes (2)
- F1. This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continued service to the Issuer.
- F2. Under the Reporting Person's arrangement with Fairmount Funds Management LLC ("Fairmount"), the Reporting Person holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.
Key Figures
Option shares granted: 34,843 shares
Exercise price: $15.22 per share
Shares underlying option: 34,843 shares
+3 more
6 metrics
Option shares granted
34,843 shares
Stock Option (Right to Buy) grant to Christopher W. Cain
Exercise price
$15.22 per share
Conversion or exercise price of the stock option
Shares underlying option
34,843 shares
Underlying common stock tied to the derivative award
Post-grant derivative holdings
34,843 derivative securities
Total options reported following the transaction
Option expiration date
June 8, 2036
Expiration date of the stock option award
Vesting trigger date
June 9, 2027
Latest vesting date, or earlier at next annual meeting
Key Terms
Stock Option (Right to Buy), vests in full, beneficial ownership, pecuniary interest, +1 more
5 terms
Stock Option (Right to Buy) financial
"This option represents a right to purchase shares of the Issuer's common stock"
vests in full financial
"which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting"
beneficial ownership financial
"The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein."
investment vehicles financial
"the Reporting Person holds the option for one or more investment vehicles managed by Fairmount"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Jade Biosciences (JBIO) disclose on this Form 4?
Jade Biosciences disclosed that director Christopher W. Cain was granted a stock option over 34,843 shares of common stock at an exercise price of $15.22 per share, reflecting a compensation-related award rather than an open-market purchase or sale.
What are the vesting terms of the new Jade Biosciences (JBIO) stock option grant?
The stock option vests in full on the earlier of June 9, 2027 or the date of Jade Biosciences’ next annual stockholder meeting, provided Christopher W. Cain continues to serve the company through that date according to the disclosure.
What is the role of Fairmount Funds Management LLC in this JBIO Form 4?
Under an arrangement with Fairmount Funds Management LLC, Christopher W. Cain holds the option for one or more Fairmount-managed investment funds and must turn over any net cash or stock from the option for the benefit of those funds, as disclosed.
Is this Jade Biosciences (JBIO) Form 4 a market purchase or sale of stock?
The Form 4 reports a grant of a stock option, not an open-market purchase or sale. It is classified as a derivative grant award, with no purchase or sale of existing common shares reported in this filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
